Lexeo Therapeutics (LXEO) addressed investors at the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 9, 2026. Chief Executive Officer Nolan Townsend, Chief Medical Officer Dr. Narinder Bhalla and Chief Financial Officer Lou Tamayo led the briefing.
The company highlighted data from the Phase I/II trial of LX2006, its gene‑therapy candidate for Friedreich’s ataxia. At six months, the high‑dose cohort achieved a 28% reduction in left ventricular mass index (LVMI), surpassing the 10% threshold deemed clinically meaningful. The pivotal trial is powered to detect a 15% LVMI effect, with simulations indicating a 99% probability of reaching that target. Patients entering the study with abnormal LVMI returned to normal values, while those with normal baseline LVMI remained stable. Functional benefit was reflected in a 2.5‑to‑3‑point gain on the modified Friedreich’s Ataxia Rating Scale (mFARS), comparable to the existing treatment SKYCLARYS, and durability extended to two years of follow‑up. No treatment‑related serious adverse events were reported at any dose level.
Lexeo also provided a status update on LX2020, aimed at PKP2‑related arrhythmogenic cardiomyopathy, a condition affecting an estimated 60,000 U.S. patients. Phase I enrollment is complete, with results expected later in 2024. Early 2024 data showed a 65% reduction in non‑sustained ventricular tachycardia (NSVT) in two patients at nine months, versus a 20% improvement seen across the broader cohort and the 20‑25% improvement typical of current anti‑arrhythmic therapy. The program uses a systemic dose in the mid‑$10^{13}$ vector genomes per kilogram range.
The firm mentioned a third pipeline effort targeting APOE4‑positive Alzheimer’s disease, an indication affecting roughly 900,000 individuals in the United States.
Manufacturing for LX2006 relies on an Sf9 baculovirus suspension platform designed for commercial scale. Management indicated that four to five manufacturing batches could satisfy the entire Friedreich’s ataxia market.
Commercialization plans include initial hires for sales and medical affairs, with broader customer‑facing staffing slated for 2027. The patient population for Friedreich’s ataxia is concentrated in a limited number of U.S. treatment centers.
Lexeo’s shares closed at $4.48, down 5.88% from the prior close of $4.76. The 52‑week range remains $3.99 to $10.99.
